Cidara Provides Corporate Update and Reports Third Quarter 2019 Financial Results

November 7, 2019 sandiegobiotech News Comments Off on Cidara Provides Corporate Update and Reports Third Quarter 2019 Financial Results
Cidara Provides Corporate Update and Reports Third Quarter 2019 Financial Results
/

SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2019 and provided an update on its corporate activities and product pipeline.

Related Articles

No Picture
News

Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2021

September 27, 2021 sandiegobiotech News Comments Off on Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2021

SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it will present new clinical and non-clinical data in three on-demand poster presentations, including data… Click here to view original post… […]

No Picture
News

Cidara Therapeutics Announces Closing of Concurrent Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock

October 13, 2021 sandiegobiotech News Comments Off on Cidara Therapeutics Announces Closing of Concurrent Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock

SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced the closing of its previously announced concurrent but separate underwritten public offerings of 17,064,511 shares of… Click here to view original post… […]